Literature DB >> 11342988

An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery.

R Kim1, N Nishimoto, A Osaki, J Kojima, S Fujii, K Inai, T Toge.   

Abstract

BACKGROUND: Recent advances in breast surgery have focused on breast conserving surgery in combination with radiotherapy. In the present study, we examine by retrospective analysis 105 patients with breast cancer who received breast conserving surgery for factors influencing disease free survival.
METHODS: The analysis was performed on 105 patients with breast cancer who received breast conserving surgery in our department, including 38 patients without radiotherapy and 67 patients treated with radiotherapy. The disease-free survival of the patients was analyzed using the Kaplan-Meier method. The relapsed patients were assessed by examining pathological features and gene expression by immunohistochemical staining.
RESULTS: There was no significant difference in the disease free survival at 5 years between patients without radiotherapy (89.6%) and with radiotherapy (94.5%). Relapse after breast conserving surgery was found in 6 patients including 4 patients without radiotherapy and 2 patients with radiotherapy. Local relapse and bone metastasis were found in 4 (3.8%) and 2 patients, respectively. Among the 4 local relapses, 1 patient had received radiotherapy and 3 patients had not. There was no significant difference between the type of relapse in terms of lymph node metastasis, hormone receptor, nuclear grade and intraductal component, but more vessel invasion was observed in the 2 cases with bone metastasis. The overexpression of apoptosis and angiogenesis genes such as p53, Bax, Bcl-XL, Bcl-2 and VEGF was not common in the relapsed patients, whereas the overexpression of drug resistance genes, either P-gp or MRP1, was found in the all patients.
CONCLUSIONS: Although radiotherapy may reduce the incidence of local relapse and increase disease free survival after breast conserving surgery, the development of an effective adjuvant chemotherapy based on drug resistance markers, is also required.

Entities:  

Mesh:

Year:  2001        PMID: 11342988     DOI: 10.1007/BF02967494

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  2 in total

1.  Long-term results after 12-year follow-up of patients treated with whole-breast and boost irradiation after breast-conserving surgery.

Authors:  Shigeo Takahashi; Yuji Murakami; Nobuki Imano; Yuko Kaneyasu; Yoshiko Doi; Masahiro Kenjo; Tomoki Kimura; Takayuki Kadoya; Koji Arihiro; Tsuyoshi Kataoka; Morihito Okada; Yasushi Nagata
Journal:  Jpn J Radiol       Date:  2016-06-17       Impact factor: 2.374

Review 2.  The Roles of MicroRNAs in Breast Cancer.

Authors:  Ryou-U Takahashi; Hiroaki Miyazaki; Takahiro Ochiya
Journal:  Cancers (Basel)       Date:  2015-04-09       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.